NCT05074940

Amivantamab in Adenoid Cystic Carcinoma

Phase II Study to Evaluate Amivantamab in Recurrent and Metastatic Adenoid Cystic Carcinoma

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: Trisha Wise-Draper · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to determine if treatment with amivantamab will be efficacious in patients with recurrent and metastatic adenoid cystic carcinoma.

Detailed description

ACC is a rare cancer of salivary glands and other glandular tissue. It is slow growing and is usually treated with surgery and radiation. However, this type of cancer tends to have a high rate of recurrence and metastatic spread, which develops over several years. We hypothesize that amivantamab, a bispecific EGFR and MET inhibitor will be efficacious in ACC. Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).

Conditions

• Salivary Gland Cancer

Interventions

Type	Name	Description
DRUG	Amivantamab	Patients will receive amivantamab at 1050mg weekly for the first cycle and biweekly thereafter (1400mg for patients ≥80kg).

Timeline

• Start date: 2022-08-05
• Primary completion: 2025-08-05
• Completion: 2028-08-05
• First posted: 2021-10-12
• Last updated: 2025-04-10

Locations

5 sites across 1 country: United States

Regulatory

• FDA-regulated drug study